국내에서 최근 분리된 황색포도알균에 대한 Arbekacin의 항균력
Antimicrobial Activities of Arbekacin against Recent Isolates of Staphylococcus aureus in Korean Hospitals
2
조회
0
다운로드
2
인용
0
참고문헌
초록
배경：Arbekacin 디스크에 의한 억제대 크기가 감수성 기준보다 작은 임상검체 유래 황색포도알균이 다수 발견되어 이들 균주에 대한 최소억제농도(minimal inhibitory concentration, MIC)를 확인하고자하였다. 방법：2004년 5월에서 7월에 고신대학교 복음병원과 부산대학교병원 환자의 임상검체에서 분리된 methicillin 내성 황색포도알균 88주와 methicillin 감수성 황색포도알균 11주를 대상으로, 한천희석법과 디스크 확산법으로 arbekacin에 대한 감수성을 시험하였다. 결과：MIC 측정 결과 대상균주 99주 모두 감수성이었다. 디스크 확산법에서는 5주(5.1%)가 중간내성(minor error)을, 2주(2.0%)가 내성(major error)을 보였다. 결론：시험 대상인 99주의 포도알균은 모두 arbekacin 감수성 (MIC ≤8 mg/L)이었으며, 디스크 확산법에서는 7%에서 major 혹은 minor error를 범할 수 있었다.
Abstract
Background: As clinical isolates of Staphylococcus aureus with reduced inhibition zone of arbekacin in disk diffusion susceptibility tests are observed frequently, we examined their susceptibility to the antibiotic by comparing the results of the agar dilution testing with those of disk diffusion testing. Methods: During the period of May through July, 2004, 88 isolates of methicillin-resistant and 11 methicillin-susceptible S. aureus were collected from clinical specimens in Pusan National University Hospital and Kosin University Gospel Hospital. Minimal inhibitory concentrations (MICs)of arbekacin were determined by the agar dilution method, and inhibition zones by the disk diffusion method. Results: All of the 99 isolates were tested susceptible to arbekacin by the agar dilution method(MIC.8mg/L). By the disk diffusion method, however, 5 isolates (5.1%) were intermediate (minor error) and 2 isolates (2.0%) resistant (major error). Conclusion: All isolates were susceptible to arbekacin, but the disk diffusion method showed 7 per cent of minor or major errors.
참고문헌 (11)
- "Staphylococcal infections", pp.1605~1610 (1996), WB Saunders Company
- "Decreased teicoplanin susceptibilityof methicillin-resistant strains of Staphylococcus aureus", 171, pp.1646~1650 (1995)
- "Arbekacin", 5, pp.227~230 (1995)
- "Compa-rartive studies of the bactericidal,morphological andpostantibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus", 39, pp.471~476 (1997)
- "Antimicrobial susceptibilities of glycopeptides,arbekacin and quinupristin", dalfopristin against Staphylo-coccus aureusisolates, 2001, pp.33, 261~266
- "Methods fordilution antimicrobial susceptibility tests for bacteria thatgrow aerobically; approved standard-sixth ed" (2005), Clinical and Laboratory Standards Institute
- "Antimicrobial activites of arbekacinagainst methicillin-resistant Staphylococcus aureus", 50, pp.1~11 (1997)
- "Bacterial sensitivity test KB Disk Eiken operation manual" (2003)
- "Epidemiological study ofArbekacin-resistant,methicillin resistant Staphylococcusaureusin Saitama Medical School Hospital", 78, pp.305~311 (2004)
- "Frequency of resistance to aminoglycoside antibioticsin Staphylococcus aureusisolated from tertiary hospitals", 34, pp.39~46 (2002)
- "Dissemination of community-acquired methicillin-resistant Staphylococcus aureusclones in Northern Norway:Sequence types 8 and 80predominate", 43, pp.2118~2124 (2005)